CONTACT
ABOUT ABBOTT
cardiovascular
MY ACCOUNT

Xience Prime™ Everolimus Eluting Coronary Stent with BTK indication

Xience Prime™ BTK Everolimus Eluting Peripheral Stent System
Xience Prime™ BTK Everolimus Eluting Peripheral Stent System
Xience Prime™ BTK Everolimus Eluting Peripheral Stent System

The Next Step in BTK Efficacy.

XIENCE Prime™ Everolimus Eluting Coronary Stent with BTK indication is clinically proven for primary stenting of focal and long lesions and is engineered for outstanding performance.1,2

Advancing BTK efficacy

Clinically Proven

  • Excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.3,4

Pre-procedure4
Post-procedure4
12 months post-procedure4

Engineered for outstanding performance

  • Leading MULTI-LINK stent design for exceptional acute performance, uncompromised radial force, and visibility5
  • Coating technology for reliable expansion and controlled Everolimus drug release
  • Innovative delivery system for excellent deliverability and confident deployment

Ordering Information

XIENCE Prime™ Everolimus Eluting Coronary Stent with BTK indication
Stock NumberStent
Diameter (mm)		Stent
Length (mm)
Nominal
Pressure (ATM)		RBP
(ATM)		Max Stent Expansion
Diameter (MM)
1012646-282.5288183.25
1012646-382.5388183.25
1012648-283.02810183.75
1012648-383.03810183.75
1012649-283.52810184.5
1012649-383.53810184.5
1012650-284.02810184.5
1012650-384.03810184.5

Discover Abbott’s Peripheral intervention technology

Contact Us

 

Abbott’s Peripheral Intervention Portfolio

References

  1. Bosiers, M et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease; J Vascular Surgery 2012;55:390-399.
  2. Bosier, M et al.Outcome of a drug eluted stent in longer below the knee lesions in patients with critical limb ischemia: J Vascular Surgery 2017;58(1):49-54
  3. M. Bosiers, DESTINY, VEITH 2010
  4. M. Bosiers, LINC 2011
  5. Tests and data on file at Abbott

 

MAT-2117132 V1.0

 

Abbott Logo

Information contained herein for distribution in Australia and New Zealand only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

Abbott Vascular division of Abbott Medical New Zealand Ltd, Grd Flr, Bldg. D, 4 Pacific Rise Mt Wellington, Auckland 1060 Tel: 0800 827 285

Abbott Vascular division of Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park NSW 2113, Tel: 1800 550 939

© 2024 Abbott. All Rights Reserved.

MAT-2105201 v6.0

Disclaimer

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

 

Do you wish to continue and enter this website?

 MAT-2408064 V1.0